T2 Biosystems Company Profile (NASDAQ:TTOO)

About T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems logoT2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TTOO
  • CUSIP: N/A
  • Web: www.t2biosystems.com
Capitalization:
  • Market Cap: $128.9 million
  • Outstanding Shares: 30,764,000
Average Prices:
  • 50 Day Moving Avg: $4.57
  • 200 Day Moving Avg: $3.92
  • 52 Week Range: $2.50 - $7.26
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.46
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.89 million
  • Price / Sales: 33.14
  • Book Value: $0.40 per share
  • Price / Book: 10.48
Profitability:
  • EBITDA: ($49,260,000.00)
  • Net Margins: -1,473.71%
  • Return on Equity: -178.83%
  • Return on Assets: -71.46%
Debt:
  • Debt-to-Equity Ratio: 3.30%
  • Current Ratio: 4.66%
  • Quick Ratio: 4.57%
Misc:
  • Average Volume: 295,934 shs.
  • Beta: 1.45
  • Short Ratio: 5.4
 

Frequently Asked Questions for T2 Biosystems (NASDAQ:TTOO)

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.01. The business earned $0.96 million during the quarter, compared to analyst estimates of $0.79 million. T2 Biosystems had a negative net margin of 1,473.71% and a negative return on equity of 178.83%. View T2 Biosystems' Earnings History.

When will T2 Biosystems make its next earnings announcement?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for T2 Biosystems.

Where is T2 Biosystems' stock going? Where will T2 Biosystems' stock price be in 2017?

7 equities research analysts have issued twelve-month price targets for T2 Biosystems' stock. Their forecasts range from $4.00 to $12.00. On average, they anticipate T2 Biosystems' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for T2 Biosystems.

What are analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:

  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (10/5/2017)
  • 2. WBB Securities analysts commented, "We Believe that in the not too distant future, doctors in residency will be trained to detect fungal and bacterial infections in hours with 95% accuracy versus the current blood culture standard of two days on average for invasive candidiasis detection, with 38% accuracy. This is the special province that T2 Biosystems, Inc. (TTOO) presently dominates. We are therefore reiterating our Strong Buy Rating and 12-Month Price Target of $12.00." (2/5/2017)

Who are some of T2 Biosystems' key competitors?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:

  • John McDonough, President, Chief Executive Officer, Director
  • Michael J. Cima Ph.D., Co-Founder, Independent Director
  • Darlene Deptula-Hicks, Chief Financial Officer, Senior Vice President, Treasurer
  • Joanne Spadoro Ph.D., Chief Operations Officer
  • Rahul K. Dhanda, Senior Vice President - Corporate Development
  • Thomas J. Lowery Ph.D., Chief Scientific Officer
  • Michael Gibbs, Vice President, General Counsel
  • Michael A. Pfaller M.D., Chief Medical Officer
  • Seymour E. Liebman, Director
  • John W. Cumming, Independent Director

How do I buy T2 Biosystems stock?

Shares of T2 Biosystems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of T2 Biosystems stock can currently be purchased for approximately $4.19.


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for T2 Biosystems (NASDAQ:TTOO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $7.00 (67.06% upside)
Consensus Price Target History for T2 Biosystems (NASDAQ:TTOO)
Price Target History for T2 Biosystems (NASDAQ:TTOO)
Analysts' Ratings History for T2 Biosystems (NASDAQ:TTOO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017HC WainwrightInitiated CoverageBuy -> Buy$8.00N/AView Rating Details
5/8/2017BTIG ResearchUpgradeSell -> Neutral$4.00HighView Rating Details
5/3/2017Cantor FitzgeraldLower Price TargetOverweight$7.00 -> $6.00HighView Rating Details
3/14/2017Morgan StanleyDowngradeEqual Weight -> Underweight$5.00HighView Rating Details
2/14/2017Canaccord GenuitySet Price TargetBuy$9.00N/AView Rating Details
2/5/2017WBB SecuritiesReiterated RatingBuy$12.00N/AView Rating Details
11/10/2016Leerink SwannReiterated RatingMarket Perform$5.00N/AView Rating Details
7/9/2016Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
12/22/2015Goldman Sachs Group, Inc. (The)Boost Price TargetNeutral$13.00 -> $14.00N/AView Rating Details
11/3/2015Jefferies Group LLCReiterated RatingBuy -> Fair Value$21.00 -> $11.48N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for T2 Biosystems (NASDAQ:TTOO)
Earnings by Quarter for T2 Biosystems (NASDAQ:TTOO)
Earnings History by Quarter for T2 Biosystems (NASDAQ TTOO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.49)N/AView Earnings Details
8/3/2017Q2 2017($0.49)($0.50)$0.79 million$0.96 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.47)($0.48)$1.55 million$0.94 millionViewListenView Earnings Details
11/1/2016Q3($0.52)($0.51)$2.03 million$1.08 millionViewN/AView Earnings Details
8/1/2016Q2($0.56)($0.58)$1.53 million$0.99 millionViewN/AView Earnings Details
5/2/2016Q1($0.54)($0.55)$1.01 million$1.10 millionViewN/AView Earnings Details
2/16/2016Q4($0.59)($0.56)$1.21 million$1.01 millionViewListenView Earnings Details
11/2/2015Q3($0.59)($0.57)$0.66 million$1.05 millionViewN/AView Earnings Details
8/4/2015Q215($0.57)($0.54)$0.34 million$0.56 millionViewN/AView Earnings Details
5/5/2015Q115($0.57)($0.53)$0.22 million$0.19 millionViewN/AView Earnings Details
2/17/2015Q414($0.44)($0.45)$0.12 millionViewN/AView Earnings Details
11/4/2014Q314($0.58)($0.71)$0.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for T2 Biosystems (NASDAQ:TTOO)
2017 EPS Consensus Estimate: ($2.06)
2018 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.59)($0.59)($0.59)
Q2 20171($0.49)($0.49)($0.49)
Q3 20171($0.49)($0.49)($0.49)
Q4 20171($0.49)($0.49)($0.49)
Q1 20181($0.53)($0.53)($0.53)
Q2 20181($0.50)($0.50)($0.50)
Q3 20181($0.48)($0.48)($0.48)
Q4 20181($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for T2 Biosystems (NASDAQ:TTOO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for T2 Biosystems (NASDAQ:TTOO)
Insider Ownership Percentage: 38.70%
Institutional Ownership Percentage: 53.02%
Insider Trades by Quarter for T2 Biosystems (NASDAQ:TTOO)
Institutional Ownership by Quarter for T2 Biosystems (NASDAQ:TTOO)
Insider Trades by Quarter for T2 Biosystems (NASDAQ:TTOO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2017Darlene M Deptula-HicksCFOBuy4,000$3.58$14,320.00View SEC Filing  
6/6/2017David B ElsbreeDirectorBuy10,000$3.50$35,000.00View SEC Filing  
6/6/2017Joanne SpadoroCOOBuy5,000$3.50$17,500.00View SEC Filing  
6/6/2017Michael Terrence GibbsGeneral CounselBuy1,000$3.51$3,510.00View SEC Filing  
3/15/2017David B ElsbreeDirectorBuy10,000$5.97$59,700.00View SEC Filing  
6/30/2016Rahul DhandaSVPSell3,589$8.16$29,286.24View SEC Filing  
3/16/2016Rahul DhandaSVPSell7,588$8.01$60,779.88View SEC Filing  
12/9/2015Aisling Capital Iii LpMajor ShareholderBuy307,692$9.75$2,999,997.00View SEC Filing  
12/9/2015David B ElsbreeDirectorBuy10,000$9.75$97,500.00View SEC Filing  
7/24/2015Polaris Venture Partners V, L.Major ShareholderSell15,399$15.04$231,600.96View SEC Filing  
7/22/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$15.22$228,284.78View SEC Filing  
7/21/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$15.42$231,284.58View SEC Filing  
7/20/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.05$240,733.95View SEC Filing  
7/17/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.26$731,651.22View SEC Filing  
7/14/2015Polaris Venture Partners V, L.Major ShareholderSell29,998$16.57$497,066.86View SEC Filing  
7/10/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.25$731,201.25View SEC Filing  
7/10/2015Thomas J LoweryInsiderSell2,000$16.03$32,060.00View SEC Filing  
7/7/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$15.91$715,902.27View SEC Filing  
7/1/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.09$724,001.73View SEC Filing  
6/30/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.22$243,283.78View SEC Filing  
6/29/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.28$244,183.72View SEC Filing  
6/26/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$17.08$768,548.76View SEC Filing  
6/23/2015Polaris Venture Partners V, L.Major ShareholderSell29,998$18.18$545,363.64View SEC Filing  
6/22/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$18.22$273,281.78View SEC Filing  
6/18/2015Thomas J LoweryInsiderSell1,000$18.65$18,650.00View SEC Filing  
6/12/2015Michael J CimaDirectorBuy1,000$18.91$18,910.00View SEC Filing  
6/12/2015Thomas J LoweryInsiderSell1,471$18.55$27,287.05View SEC Filing  
5/8/2015Michael A PfallerInsiderSell15,440$16.31$251,826.40View SEC Filing  
4/20/2015Thomas J LoweryInsiderSell1,000$18.43$18,430.00View SEC Filing  
3/4/2015David B ElsbreeDirectorBuy1,450$15.05$21,822.50View SEC Filing  
11/13/2014David B ElsbreeDirectorBuy1,500$14.75$22,125.00View SEC Filing  
8/12/2014Aisling Capital Iii LpMajor ShareholderBuy454,545$11.00$4,999,995.00View SEC Filing  
8/12/2014Sarah O KalilCOOBuy15,000$11.00$165,000.00View SEC Filing  
8/12/2014Thomas J CarellaDirectorBuy909,090$11.00$9,999,990.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for T2 Biosystems (NASDAQ:TTOO)
Latest Headlines for T2 Biosystems (NASDAQ:TTOO)
Source:
DateHeadline
finance.yahoo.com logoT2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call Date
finance.yahoo.com - October 17 at 8:25 AM
finance.yahoo.com logoETFs with exposure to T2 Biosystems, Inc. : October 13, 2017
finance.yahoo.com - October 14 at 8:51 AM
finance.yahoo.com logoClinicians Discuss Positive Impact of T2MR Platform on Sepsis Care at IDWeek 2017
finance.yahoo.com - October 13 at 9:36 AM
americanbankingnews.com logoDexCom (DXCM) and T2 Biosystems (TTOO) Critical Analysis
www.americanbankingnews.com - October 12 at 8:08 PM
americanbankingnews.com logoT2 Biosystems (TTOO) vs. Its Rivals Financial Analysis
www.americanbankingnews.com - October 8 at 12:28 PM
americanbankingnews.com logoT2 Biosystems, Inc. (TTOO) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - October 7 at 11:54 PM
americanbankingnews.com logoT2 Biosystems Inc (TTOO) Expected to Post Quarterly Sales of $1.09 Million
www.americanbankingnews.com - October 4 at 1:56 PM
finance.yahoo.com logoStudy Published in Journal of Antimicrobial Stewardship Shows Patients Diagnosed with T2Candida Panel Treated More Than Eight Times Faster
finance.yahoo.com - October 3 at 2:01 PM
americanbankingnews.com logoT2 Biosystems, Inc. (TTOO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 30 at 5:12 AM
finance.yahoo.com logoT2 Biosystems Announces Presentations at IDWeek 2017
finance.yahoo.com - September 23 at 10:20 AM
finance.yahoo.com logoT2 Biosystems to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 19 at 8:50 AM
streetinsider.com logoT2 Biosystems (TTOO) Prices 4.38M Common Stock Offering at $4/Share
www.streetinsider.com - September 17 at 8:51 AM
americanbankingnews.com logoT2 Biosystems (TTOO) and Its Competitors Head to Head Review
www.americanbankingnews.com - September 17 at 8:20 AM
finance.yahoo.com logoT2 Biosystems Prices Secondary Offering
finance.yahoo.com - September 16 at 9:55 AM
americanbankingnews.com logoInvacare Corporation (IVC) and T2 Biosystems (TTOO) Head-To-Head Review
www.americanbankingnews.com - September 15 at 8:46 PM
finance.yahoo.com logoT2 Biosystems Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 15 at 10:22 AM
finance.yahoo.com logoT2 Biosystems Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 15 at 10:22 AM
finance.yahoo.com logoT2 Biosystems' stock sinks on heavy volume after share offering prices at deep discount
finance.yahoo.com - September 15 at 10:22 AM
americanbankingnews.com logo$1.09 Million in Sales Expected for T2 Biosystems, Inc. (TTOO) This Quarter
www.americanbankingnews.com - September 15 at 7:10 AM
finance.yahoo.com logoWith FDA filing, Lexington firm targets a scourge of hospitals: sepsis
finance.yahoo.com - September 13 at 10:30 AM
finance.yahoo.com logoT2 Biosystems Submits 510(k) Application to the FDA for Review of T2Bacteria Panel
finance.yahoo.com - September 12 at 11:24 AM
finance.yahoo.com logoT2 Biosystems Announces Collaboration with CDC to Detect Emerging Superbug Candida auris
finance.yahoo.com - September 6 at 9:27 AM
finance.yahoo.com logoT2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials
finance.yahoo.com - September 6 at 9:27 AM
americanbankingnews.com logoT2 Biosystems, Inc. (TTOO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 5 at 4:56 AM
finance.yahoo.com logoETFs with exposure to T2 Biosystems, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 10:08 AM
finance.yahoo.com logoT2 Biosystems Announces 11 New Patents Granted in 2017
finance.yahoo.com - August 31 at 11:20 AM
finance.yahoo.com logoT2 Biosystems, Inc. :TTOO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:54 AM
finance.yahoo.com logoT2 Biosystems and Aridis Pharmaceuticals, Inc. Join Antimicrobials Working Group
finance.yahoo.com - August 16 at 8:28 AM
americanbankingnews.com logoT2 Biosystems, Inc. (NASDAQ:TTOO) Sees Large Growth in Short Interest
www.americanbankingnews.com - August 13 at 2:20 AM
finance.yahoo.com logoEdited Transcript of TTOO earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 12 at 1:27 AM
americanbankingnews.com logoT2 Biosystems, Inc. (TTOO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - August 11 at 10:56 AM
americanbankingnews.com logoT2 Biosystems, Inc. (NASDAQ:TTOO) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 5 at 2:14 PM
finance.yahoo.com logoT2 Biosystems Reports Second Quarter 2017 Financial Results; Provides Company Update
finance.yahoo.com - August 4 at 9:20 AM
finance.yahoo.com logoT2 Biosystems reports 2Q loss
finance.yahoo.com - August 4 at 9:20 AM
finance.yahoo.com logoT2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - August 2 at 8:07 AM
finance.yahoo.com logoT2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member
finance.yahoo.com - July 28 at 9:12 AM
americanbankingnews.com logoK2M Group Holdings (KTWO) & T2 Biosystems (NASDAQ:TTOO) Financial Analysis
www.americanbankingnews.com - July 27 at 10:33 PM
americanbankingnews.com logoT2 Biosystems, Inc. (NASDAQ:TTOO) Set to Announce Earnings on Thursday
www.americanbankingnews.com - July 27 at 8:02 AM
finance.yahoo.com logoT2 Biosystems Announces 2017 Second Quarter Financial and Operational Results Release and Conference Call Date
finance.yahoo.com - July 20 at 9:01 AM
americanbankingnews.com logoT2 Biosystems, Inc. (TTOO) Expected to Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - July 18 at 2:43 PM
finance.yahoo.com logoT2 BIOSYSTEMS RECEIVES CE MARK FOR T2BACTERIA™ PANEL ENABLING COMMERCIALIZATION IN EUROPE
finance.yahoo.com - July 18 at 9:22 AM
americanbankingnews.com logoT2 Biosystems, Inc. (NASDAQ:TTOO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 11:30 AM
finance.yahoo.com logoETFs with exposure to T2 Biosystems, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 9:26 AM
streetinsider.com logoT2 Biosystems (TTOO) Presents New T2Sepsis Solution Clinical & Economic Results at ASM Microbe 2017 Conference
www.streetinsider.com - June 8 at 1:32 AM
streetinsider.com logoT2 Biosystems, Inc (TTOO) PT Lowered to $6 at Cantor Fitzgerald; 'Lower Than Expected 1Q17 Results, T2Bacteria Progresses'
www.streetinsider.com - May 3 at 11:42 PM
marketbeat.com logoT2 Biosystems reports 1Q loss
marketbeat.com - May 2 at 6:13 PM
streetinsider.com logoT2 Biosystems (TTOO) Names Darlene Deptula-Hicks as CFO
www.streetinsider.com - May 1 at 7:29 PM
biz.yahoo.com logoT2 BIOSYSTEMS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 15 at 10:48 PM
streetinsider.com logoCantor Fitzgerald Reiterates Overweight on T2 Biosystems (TTOO) Following CFO Resignation - StreetInsider.com
www.streetinsider.com - March 9 at 8:58 PM
biz.yahoo.com logoT2 BIOSYSTEMS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princip
biz.yahoo.com - March 9 at 3:27 AM

Social

Chart

T2 Biosystems (TTOO) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.